Overview

Transplantation Using Reduced Intensity Approach for Patients With Sickle Cell Disease From Mismatched Family Donors of Bone Marrow

Status:
Recruiting

Trial end date:
2023-07-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to learn if it is possible and safe to treat persons with severe sickle cell disease (SCD) by bone marrow transplant (BMT) from human leukocyte antigen (HLA) half-matched related donors. Preparation before transplant includes the chemotherapy drugs hydroxyurea, fludarabine, thiotepa, anti-thymocyte globulin, and cyclophosphamide. It also includes radiation.

Phase:

Phase 2

Details

Lead Sponsor:

Emory University

Treatments:

Antilymphocyte Serum
Cyclophosphamide
Fludarabine
Fludarabine phosphate
Hydroxyurea
Thiotepa
Thymoglobulin
Vidarabine